Jump to main content
Takeda, in alignment with the U.S. Food and Drug Administration (FDA), will close the U.S. Special Use Program (SUP) for NATPARA® (parathyroid hormone) for Injection at the end of 2025. TAKEDA WILL CEASE SHIPMENTS OF NATPARA BY DECEMBER 31, 2025 AND NATPARA WILL NO LONGER BE AVAILABLE TO SUP PATIENTS. Learn How This May Affect You
NATPARA logo.

NATPARA® is a parathyroid hormone indicated as an adjunct to calcium and vitamin D to control hypocalcemia in patients with hypoparathyroidism. Because of the potential risk of osteosarcoma, NATPARA is recommended only for patients who cannot be well-controlled on calcium supplements and active forms of vitamin D alone. NATPARA was not studied in patients with hypoparathyroidism caused by calcium-sensing receptor mutations. NATPARA was not studied in patients with acute post-surgical hypoparathyroidism.

See full indication

See less indication

NATPARA® is a parathyroid hormone indicated as an adjunct to calcium and vitamin D to control hypocalcemia in patients with hypoparathyroidism. Because of the potential risk of osteosarcoma, NATPARA is recommended only for patients who cannot be well-controlled on calcium supplements and active forms of vitamin D alone. NATPARA was not studied in patients with hypoparathyroidism caused by calcium-sensing receptor mutations. NATPARA was not studied in patients with acute post-surgical hypoparathyroidism.

See full indication

See less indication

NATPARA logo.

Injection Training

We help prepare your patients to self-administer NATPARA

Nurse showing the NATPARA kit.

How we can help your patients get started

All patients prescribed NATPARA are provided injection training by a Registered Nurse through the NATPARA Nurse Educator team. A Patient Support Manager works with the Nurse Educator team to assign each patient a specially trained NATPARA Nurse Educator. The Nurse Educator will contact the patient within 2 business days of receiving his/her NATPARA shipment to schedule up to 4 sessions of complimentary training in the patient's home, including:

Nurse showing the NATPARA kit.
  • Delivering the injection device and demonstrating how to assemble it
  • Walking through the reconstitution and administration process for the first 3 cartridges (Days 1, 15, and 29 of treatment)
  • Calling the patient after each training to check in and answer any questions
  • Providing materials to help patients take an active role in their treatment

When patients are mixing the cartridge alone for the first time, there will be a Nurse Educator on the phone

Questions or concerns?

Please call 1-866-888-0660, Monday through Friday,
8:30 AM to 8:00 PM ET

Learn About Dosing & Administration

Reference: 1. NATPARA [package insert]. Shire Pharmaceuticals, Inc.

NATPARA® and the NATPARA Logo® are registered trademarks of Takeda Pharmaceuticals, U.S.A,. Inc.

Takeda logo.

©2025 Takeda Pharmaceuticals U.S.A., Inc., 500 Kendall Street, Cambridge, MA 02142. 1-877-TAKEDA-7 (1-877-825-3327). All rights reserved. Takeda and the Takeda Logo are registered trademarks of Takeda Pharmaceutical Company Limited.
US-NAT-0590v1.0 01/25

All content in this site, including text, images, graphics, sound files, and their arrangement, is copyrighted and owned by Takeda and is protected by international copyright laws. All other intellectual property rights are reserved. The content may not be copied for commercial use or distribution, nor may these objects be downloaded, modified, or posted to other sites.

This site is intended solely for US residents and is governed solely by US laws and government regulations. Please see our Legal Notice for more information. While Takeda Pharmaceutical Company Limited makes reasonable efforts to include accurate, up-to-date information on this site, Takeda Pharmaceutical Company Limited makes no warranties or representations as to its accuracy. Takeda Pharmaceutical Company Limited assumes no liability for any errors or omissions in the content of this site.